(function(){
			var content_array=["<p><strong>About CAM2029<\/strong><br \/> CAM2029 is a novel, ready-to-use, long-acting octreotide product for treatment of acromegaly and neuroendocrine tumors (NETs) based on Camurus' proprietary FluidCrystal&reg; delivery system. Octreotide chloride, the active ingredient of CAM2029 is a synthetic, cyclic octapeptide, an eight amino acid analogue of the peptide hormone somatostatin. The CAM2029 product is designed for easy and patient-friendly drug administration. While traditional depot therapeutics frequently comprise complex microsphere technology for intramuscular injection, Camurus' FluidCrystal&reg; depot allows for subcutaneous injection of a small volume liquid that transforms into a biodegradable liquid crystal gel at the site of injection. Thereby the drug compound is effectively encapsulated, providing rapid onset and long-acting octreotide release.<\/p>\r\n<p><strong>About Camurus<\/strong><br \/> Camurus is a research-based pharmaceutical company dedicated to developing innovative therapeutics for diseases with high unmet medical needs. The company's current pipeline includes products for treatment of pain, opiate addiction, cancer and for use in endocrinology. Based on its advanced nanoscale drug-delivery technology platform, FluidCrystal&reg;, Camurus is also active in a number of development partnerships and research collaborations with international pharmaceutical and biotech companies.<\/p>\r\n<p>For further information, please contact:<br \/> Fredrik Tiberg, President &amp; CEO<br \/> Tel: +46(0)46-286-4692<br \/> <a rel=\"nofollow\" href=\"mailto:fredrik.tiberg@camurus.com\" target=\"_blank\">fredrik.tiberg@camurus.com<\/a><br \/> <a rel=\"nofollow\" href=\"http:\/\/www.camurus.com\/\" target=\"_blank\">http:\/\/www.camurus.com<\/a><\/p>"];
			$("#dvExtra").html(content_array[0]);})();